Skip to content
The Policy VaultThe Policy Vault

Vitrakvi (larotrectinib) — Medica

solid tumors

Initial criteria

  • The tumor is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion
  • Patient meets ONE of the following: the tumor is metastatic OR surgical resection of tumor will likely result in severe morbidity

Approval duration

1 year